Virogin Biotech
Virogin Biotech is a biotechnology company focused on developing cancer therapies using HSV-1 based oncolytic viruses and mRNA-based therapeutics, with several candidates in various stages of clinical trials.
Company Overview
Virogin Biotech is a biotechnology company that focuses on developing innovative therapies for cancer treatment. The company leverages two primary platforms: HSV-1 based oncolytic viruses and mRNA-based therapeutics. Its mission centers on producing novel treatments to combat cancer.
Oncolytic HSV-1 Platform
Virogin Biotech's HSV-1 based oncolytic virus platform is one of its major therapeutic development areas. The company currently has two candidates undergoing clinical trials. The leading candidate, VG161, is in Phase 2 clinical trials and has received FDA Fast Track Designation and Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma. Additionally, IND approvals have been granted by both the U.S. FDA and Chinese NMPA for VG201 and VG161.
mRNA-Based Therapeutics
Virogin Biotech's mRNA-based therapeutic platform has successfully completed preclinical proof of concept stages. This platform is aimed at developing innovative therapies for various types of cancer. The company has also published notable research in prominent scientific journals, including a study on the development of a Monkeypox mRNA vaccine in Nature Communications.
Clinical Trials
Virogin Biotech has significant advancements in its clinical trial pipeline. The most advanced candidate, VG161 from the oncolytic HSV-1 platform, is currently in Phase 2. Virogin also announced the dosing of its first US patient in a Phase 1 study of VG201, which is aimed at treating patients with advanced solid tumors. These trials highlight the company’s commitment to progressing its drug candidates through the necessary stages to bring innovative treatments to market.
Research Publications
Virogin Biotech has contributed to the scientific community with several publications. Among them is research on a Monkeypox mRNA vaccine published in Nature Communications. Additionally, a publication in Vaccines detailed a Homologous Prime Boost Strategy using HER-2 expressing Oncolytic HSV-1, showcasing the company's dedication to advancing cancer therapy research.